• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Herbal Medicines for Irinotecan-Induced Diarrhea.用于治疗伊立替康所致腹泻的草药药物。
Front Pharmacol. 2019 Mar 29;10:182. doi: 10.3389/fphar.2019.00182. eCollection 2019.
2
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.在洛哌丁胺治疗失败后,奥曲肽对伊立替康所致腹泻的控制作用
Support Care Cancer. 2001 Jun;9(4):258-60. doi: 10.1007/s005200000220.
3
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.布地奈德对伊立替康(CPT - 11)和5 - 氟尿嘧啶所致腹泻且洛哌丁胺治疗无效的患者有显著疗效。
Ann Oncol. 1999 Oct;10(10):1251-3. doi: 10.1023/a:1008390308416.
4
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.晚期结直肠癌患者伊立替康所致迟发性腹泻的病理生理学与治疗:一项前瞻性评估
J Clin Oncol. 1998 Aug;16(8):2745-51. doi: 10.1200/JCO.1998.16.8.2745.
5
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.使用大剂量洛哌丁胺控制腹泻对伊立替康(CPT-11)进行高剂量递增。
J Natl Cancer Inst. 1994 Mar 16;86(6):446-9. doi: 10.1093/jnci/86.6.446.
6
Novel agents that potentially inhibit irinotecan-induced diarrhea.可能抑制伊立替康所致腹泻的新型药物。
Curr Med Chem. 2005;12(11):1343-58. doi: 10.2174/0929867054020972.
7
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.喜树碱类似物伊立替康每3周给药一次在癌症患者中的I期和药理学研究。
J Clin Oncol. 1995 Jan;13(1):210-21. doi: 10.1200/JCO.1995.13.1.210.
8
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.采用拓扑异构酶-I抑制剂伊立替康(CPT-11)进行化疗,用于治疗难治性和复发性非霍奇金淋巴瘤。
Leuk Lymphoma. 2001 Aug;42(4):577-86. doi: 10.3109/10428190109099317.
9
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.难治性CPT - 11诱导腹泻患者对奥曲肽的治疗反应。
Invest New Drugs. 2001;19(4):341-3. doi: 10.1023/a:1010678214152.
10
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.活性炭预防伊立替康所致腹泻的II期研究。
J Clin Oncol. 2004 Nov 1;22(21):4410-7. doi: 10.1200/JCO.2004.11.125.

引用本文的文献

1
Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024.伊立替康的安全性评估:2004年至2024年期间使用FAERS和JADER数据库进行的真实世界不成比例性分析。
Front Pharmacol. 2025 Jun 9;16:1516449. doi: 10.3389/fphar.2025.1516449. eCollection 2025.
2
β-Glucuronidase-Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool.表达β-葡萄糖醛酸酶的罗伊氏乳杆菌通过耗尽再生上皮干细胞/祖细胞池引发伊立替康肠毒性。
Adv Sci (Weinh). 2025 Apr 26:e2411052. doi: 10.1002/advs.202411052.
3
Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment.管理伊立替康所致腹泻:癌症治疗中治疗干预措施的全面综述
Pharmaceuticals (Basel). 2025 Mar 2;18(3):359. doi: 10.3390/ph18030359.
4
Restore intestinal steady-state: new advances in the clinical management of chemotherapy-associated diarrhea and constipation.恢复肠道稳态:化疗相关性腹泻和便秘临床管理的新进展
J Mol Histol. 2025 Mar 8;56(2):101. doi: 10.1007/s10735-025-10367-w.
5
Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy.利用蜂胶及其多酚/类黄酮化合物联合化疗和放疗克服耐药途径的潜在策略。
Nutrients. 2024 Oct 31;16(21):3741. doi: 10.3390/nu16213741.
6
Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.生姜泻心汤对小细胞肺癌患者伊立替康所致腹泻的疗效及安全性:一项多中心、随机、双盲、安慰剂对照试验
Chin Med. 2024 Nov 4;19(1):153. doi: 10.1186/s13020-024-01025-6.
7
An optimal combination of four active components in Huangqin decoction for the synergistic sensitization of irinotecan against colorectal cancer.黄芩汤中四种活性成分对伊立替康抗结直肠癌的协同增敏作用的最佳组合。
Chin Med. 2024 Jul 2;19(1):94. doi: 10.1186/s13020-024-00967-1.
8
Banxia Xiexin decoction combined with 5-ASA protects against CPT-11-induced intestinal dysfunction in rats via inhibiting TLR4/NF-κB signaling pathway.半夏泻心汤联合 5-ASA 通过抑制 TLR4/NF-κB 信号通路对 CPT-11 诱导的大鼠肠道功能障碍的保护作用。
Immun Inflamm Dis. 2024 Jun;12(6):e1208. doi: 10.1002/iid3.1208.
9
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.伊立替康所致腹泻的防护干预措施的效果:系统评价和荟萃分析。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241242110. doi: 10.1177/15347354241242110.
10
The role of gut microbiota and metabolites in cancer chemotherapy.肠道微生物群和代谢物在癌症化疗中的作用。
J Adv Res. 2024 Oct;64:223-235. doi: 10.1016/j.jare.2023.11.027. Epub 2023 Nov 26.

本文引用的文献

1
Flavonoid-rich fraction of Bauhinia forficata Link leaves prevents the intestinal toxic effects of irinotecan chemotherapy in IEC-6 cells and in mice.密花豆叶富黄酮部位预防伊立替康化疗对 IEC-6 细胞和小鼠的肠道毒性作用。
Phytother Res. 2019 Jan;33(1):90-106. doi: 10.1002/ptr.6202. Epub 2018 Oct 3.
2
Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.半夏泻心汤对预防和控制复发性小细胞肺癌中伊立替康引起的迟发性腹泻有效。
Integr Cancer Ther. 2018 Dec;17(4):1109-1114. doi: 10.1177/1534735418801532. Epub 2018 Sep 19.
3
Effect of hesperetin on inflammatory and oxidative status in trinitrobenzene sulfonic acid-induced experimental colitis model.橙皮素对三硝基苯磺酸诱导的实验性结肠炎模型炎症和氧化状态的影响
Cell Mol Biol (Noisy-le-grand). 2018 Aug 30;64(11):58-65.
4
Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition.一石二鸟:橙皮素可缓解化疗引起的腹泻并增强肿瘤抑制作用。
Oncotarget. 2018 Feb 23;9(46):27958-27973. doi: 10.18632/oncotarget.24563. eCollection 2018 Jun 15.
5
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.生姜泻心汤对携带UGT1A1*28和UGT1A1*6基因多态性患者伊立替康所致毒性的影响。
J Tradit Chin Med. 2017 Feb;37(1):35-42. doi: 10.1016/s0254-6272(17)30024-9.
6
Inhibitory Effects of Baicalein Derived from Japanese Traditional Herbal Medicine on SN-38 Glucuronidation.源自日本传统草药的黄芩苷对SN-38葡萄糖醛酸化的抑制作用。
J Pharm Pharm Sci. 2018;21(1):195-206. doi: 10.18433/jpps29783.
7
Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.生姜泻心汤通过调节代谢酶和转运体改变伊立替康的药代动力学:一种减轻胃肠道毒性的多靶点疗法
Front Pharmacol. 2017 Oct 27;8:769. doi: 10.3389/fphar.2017.00769. eCollection 2017.
8
Prevalence and Predictors of Herbal Medicine Use Among Adults in the United States.美国成年人使用草药的患病率及预测因素。
J Patient Exp. 2017 Sep;4(3):108-113. doi: 10.1177/2374373517706612. Epub 2017 Jun 5.
9
Quantitative Evaluation of the Compatibility Effects of Huangqin Decoction on the Treatment of Irinotecan-Induced Gastrointestinal Toxicity Using Untargeted Metabolomics.基于非靶向代谢组学对黄芩汤治疗伊立替康所致胃肠道毒性的配伍效应进行定量评价
Front Pharmacol. 2017 Apr 21;8:211. doi: 10.3389/fphar.2017.00211. eCollection 2017.
10
HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.黄芩汤通过调节胆汁酸代谢稳态减轻伊立替康诱导的胃肠道毒性。
Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017.

用于治疗伊立替康所致腹泻的草药药物。

Herbal Medicines for Irinotecan-Induced Diarrhea.

作者信息

Tang Liu, Li Xiaolei, Wan Liping, Xiao Yao, Zeng Xin, Ding Hong

机构信息

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.

出版信息

Front Pharmacol. 2019 Mar 29;10:182. doi: 10.3389/fphar.2019.00182. eCollection 2019.

DOI:10.3389/fphar.2019.00182
PMID:30983992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6450188/
Abstract

Irinotecan (CPT-11), a water-soluble derivative of camptothecin, belongs to the class of DNA topoisomerase I inhibitors and has been approved worldwide for the treatment of advanced colorectal cancer, lung cancer, and malignant lymphoma. Although CPT-11-based chemotherapy is widely used, severe gastrointestinal (GI) toxicity, especially late-onset diarrhea, is a common adverse reaction, limiting clinical application of the drug. The incidence of grade 3 or 4 diarrhea is high, with 20-40% of CPT-11-treated patients experiencing this adverse effect. High-dose loperamide and octreotide are generally recommended for treatment of CPT-11-induced diarrhea. However, in clinical practice, loperamide is associated with a significant failure rate and the beneficial effects of octreotide are controversial. An accumulating number of recent studies have suggested that medicinal herbs and their derived phytocompounds may be effective complementary treatments for CPT-11-induced diarrhea. In this mini-review, we briefly summarize currently available literatures regarding the formulae and herbs/natural products used as adjuvants in animal and clinical studies for the treatment of diarrhea caused by CPT-11.

摘要

伊立替康(CPT-11)是喜树碱的水溶性衍生物,属于DNA拓扑异构酶I抑制剂类,已在全球范围内获批用于治疗晚期结直肠癌、肺癌和恶性淋巴瘤。尽管基于CPT-11的化疗被广泛应用,但严重的胃肠道(GI)毒性,尤其是迟发性腹泻,是一种常见的不良反应,限制了该药物的临床应用。3级或4级腹泻的发生率很高,20%-40%接受CPT-11治疗的患者会出现这种不良反应。高剂量洛哌丁胺和奥曲肽通常被推荐用于治疗CPT-11引起的腹泻。然而,在临床实践中,洛哌丁胺的失败率很高,奥曲肽的疗效也存在争议。最近越来越多的研究表明,草药及其衍生的植物化合物可能是治疗CPT-11引起的腹泻的有效辅助疗法。在本综述中,我们简要总结了目前关于在动物和临床研究中用作辅助治疗CPT-11引起的腹泻的方剂和草药/天然产物的文献。